- ISIN
- US45781K2042
- CUSIP
- 45781K204
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 17, 2019
Highlights
- Market Cap
- $160.89M
- Enterprise Value
- $164.17M
- EPS (TTM)
- -$1.10
- Total Revenue (TTM)
- $18.59M
- Gross Profit (TTM)
- -$3.04M
- EBITDA (TTM)
- -$102.68M
- Year Range
- $1.17 - $2.63
- Target Price
- $5.00
- ROA (TTM)
- -157.02%
- ROE (TTM)
- 453.76%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IPHA Performance Chart
Innate Pharma (IPHA) is up 0.6% since the beginning of the year. At $2 per share, IPHA is trading 33.1% below its 52-week high of $3. Investors who bought $1,000 worth of IPHA shares 5 years ago would now be looking at an investment worth $468.
Loading charts...
Returns By Period
Innate Pharma (IPHA) has returned 0.57% so far this year and -17.37% over the past 12 months.
Innate Pharma
- 1D
- -3.30%
- 1M
- 23.08%
- YTD
- 0.57%
- 6M
- -7.37%
- 1Y
- -17.37%
- 3Y*
- -15.62%
- 5Y*
- -14.09%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
IPHA Monthly Returns History
Based on dividend-adjusted daily data since Oct 17, 2019, IPHA's average daily return is +0.07%, while the average monthly return is -0.18%.
Historically, 42% of months were positive and 58% were negative. The best month was Dec 2022 with a return of +73.5%, while the worst month was Sep 2020 at -38.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, IPHA closed higher 46% of trading days. The best single day was Dec 13, 2024 with a return of +94.8%, while the worst single day was Sep 8, 2020 at -26.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.57% | -6.28% | -25.36% | 12.50% | 27.08% | -3.83% | 0.57% | ||||||
| 2025 | -0.54% | 15.85% | -16.04% | 25.28% | -1.79% | -17.12% | 16.25% | 2.37% | -10.65% | 2.07% | -1.02% | -10.26% | -4.89% |
| 2024 | -4.29% | -2.24% | 9.92% | -19.79% | 18.61% | -29.20% | 10.57% | 6.99% | -0.22% | -17.42% | -18.56% | 19.48% | -34.29% |
| 2023 | -7.64% | -14.37% | -3.39% | 3.51% | -0.34% | 4.59% | -4.39% | -0.95% | -13.12% | -2.37% | -2.83% | 16.67% | -24.93% |
| 2022 | -16.89% | -10.03% | -1.47% | -14.58% | -7.32% | 1.50% | 18.51% | -16.25% | -25.37% | 7.50% | 0.00% | 73.49% | -18.20% |
| 2021 | -0.00% | 12.22% | -6.10% | -1.62% | -7.78% | -15.86% | 0.91% | 9.64% | 69.51% | -6.00% | -14.48% | -8.06% | 11.49% |
Benchmark Metrics
Innate Pharma has an annualized alpha of 5.51%, beta of 0.77, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 18, 2019.
- This stock participated in 99.58% of S&P 500 Index downside but only -2.70% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 5.51%
- Beta
- 0.77
- R²
- 0.03
- Upside Capture
- -2.70%
- Downside Capture
- 99.58%
Return for Risk
Risk / Return Rank
IPHA ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Innate Pharma (IPHA) and compare them to S&P 500 Index.
| IPHA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.43 | ||
| Sortino ratioReturn per unit of downside risk | -2.68 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.41 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | -0.34 | 2.93 | -3.27 |
| Martin ratioReturn relative to average drawdown | -0.71 | 13.52 | -14.23 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Innate Pharma. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Innate Pharma was 85.73%, occurring on Mar 20, 2026. The portfolio has not yet recovered.
The current Innate Pharma drawdown is 78.54%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -85.73%Mar 2026 | 5y 10mo | — | 6y 24dMay 2020 - now |
COVID crash2020 | -52.20%Mar 2020 | 26d | 1mo 25d | 2mo 21dFeb 2020 - May 2020 |
2019 correction2019 | -12.06%Nov 2019 | 6d | 1mo 15d | 1mo 21dNov 2019 - Jan 2020 |
2020 correction2020 | -10.16%Jan 2020 | 6d | 14d | 20dJan 2020 - Feb 2020 |
2020 pullback2020 | -9.99%Jan 2020 | 0s | 14d | 14dJan 2020 - Jan 2020 |
Drawdown Indicators
| IPHA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.73% | -56.78% | -28.95% |
Max Drawdown (1Y)Largest decline over 1 year | -50.84% | -9.10% | -41.74% |
Max Drawdown (3Y)Largest decline over 3 years | -66.57% | -18.90% | -47.67% |
Max Drawdown (5Y)Largest decline over 5 years | -85.56% | -25.43% | -60.13% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -78.54% | -0.74% | -77.80% |
Average DrawdownAverage peak-to-trough decline | -57.81% | -10.72% | -47.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.68% | 1.97% | +22.71% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Innate Pharma over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Innate Pharma is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IPHA relative to other companies in the Biotechnology industry. Currently, IPHA has a P/S ratio of 8.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IPHA
Add Innate Pharma to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IPHA